Archives : mai 2014

Human trials

Click on the article to read

article biosantech

Biosantech est présent au congrès ISHEID

stand

Health. HIV, new hope On

It does not cure AIDS but avoid dying. It is the promise of French society Biosantech which is testing a therapeutic vaccine against HIV. To date, this is one of the most advanced tracks in the world.

Read more

Crowd funding : A startup opens its capital to fund a vaccine against AIDS

Biosantech The company, founded in 2011, launched a crowdfunding campaign to finance a therapeutic vaccine against AIDS. The company is a partner of the crowdfunding platform bordelaise « Happy Capital ».

It does not cure AIDS but avoid dying. It is the promise of French society Biosantech which is testing a therapeutic vaccine against HIV. To date, this is one of the most advanced tracks in the world.

Read more

Vaccine against AIDS: the Biosantech bet that takes everyone to court

Will we one day cure AIDS? Biosantech believes. The small French company leads the most advanced tests at present in the world to develop a therapeutic vaccine. But stands out as an UFO in the world of research.

This is the most advanced track vaccine against HIV today. Presented on Monday on the sidelines of the seventh international conference speaking against HIV and hepatitis, held this week in Montpellier, the project of French society Biosantech a sensation

Read more

HIV : A French therapeutic vaccine testing

A therapeutic vaccine against HIV is being tested at the hospital of the Conception in Marseille. A project of the Biosantech company, which is one of the most advanced vaccine against AIDS tracks today, as it was presented at the International Francophone Conference on HIV and hepatitis, held Montpellier (27-30 April 2014). Indeed, the vaccine is in phase 2 clinical trial, that is to say tested on HIV-infected patients, in order to validate its effectiveness. Since September 2013, 48 HIV-positive patients were included and divided into four groups to receive three injections of the vaccine at different doses (ie 11, 33 and 99 micrograms of active ingredient) or placebo. The objective is to determine what the most effective dose. The results will be presented in early 2015. The second phase of the Phase 2 trial will then be extended to 80 patients to verify the absence of side effects, the production of antibodies and the level of viremia after two months stopping HAART.

This vaccine is therapeutic, not preventive. It is therefore intended to already infected with HIV patients. It targets the Tat protein, which protects the cells infected with HIV from being attacked and destroyed by the immune system. The vaccine neutralizes this protein, thus allowing to restore the immunity of AIDS patients and eliminate the cells infected with HIV. Three injections of vaccine would be sufficient to stabilize the condition of an HIV positive patient. A protocol that, if successful, would reduce or even waive the triple therapy.

A French SME wants to defeat AIDS

A French SME wants to defeat AIDS

Founded in 2011, is a small Biosantech SMEs aims to defeat AIDS with a vaccine that is being developed. This would be a therapeutic vaccine that is to say that we administer to people already infected with the virus to counter his misdeeds. This would treat HIV-positive but not to prevent the spread of the disease.

Read more

A French SME wants to defeat AIDS

Founded in 2011, is a small Biosantech SMEs aims to defeat AIDS with a vaccine that is being developed. This would be a therapeutic vaccine that is to say that we administer to people already infected with the virus to counter his misdeeds. This would treat HIV-positive but not to prevent the spread of the disease.

Read more